Physician profile
Aurelio Campos
NPI 1265446280
$6,099.65
in general payments reported to CMS, 2019-2025
29 companies · $534 in 2025
The $534 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $628 · 2021: $1,229 · 2022: $1,026 · 2023: $1,322 · 2024: $1,038 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,790.22 | 2020-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,249.76 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.55 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $393.01 | 2021-2023 | |
| Lilly USA, LLC | $376.05 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $220.14 | 2022-2025 | |
| Astellas Pharma US INC | $200.51 | 2021-2024 | Veozah |
| Allergan, INC. | $196.31 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $139.11 | 2024 | Rytary, Crexont |
| Biohaven Pharmaceuticals, INC. | $131.30 | 2021 | |
| Pfizer INC. | $123.21 | 2019-2024 | |
| Amarin Pharma, INC. | $98.28 | 2020-2021 | |
| Lundbeck LLC | $83.16 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $62.63 | 2022-2025 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.50 | 2019-2024 | Relistor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.70 | 2021-2024 | Farxiga |
| Vanda Pharmaceuticals INC. | $46.05 | 2024-2025 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $42.11 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $38.21 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $35.43 | 2021-2022 | |
| Eisai INC. | $33.79 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.94 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $21.52 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $16.64 | 2022 | |
| Merck Sharp & Dohme LLC | $16.21 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.35 | 2022 | |
| Qol Medical, LLC | $7.29 | 2019 | |
| Sumitomo Pharma America, INC. | $5.69 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurelio Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.